Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARγ

Journal of Clinical Investigation

Volumn 114, Issue 2, 2004, Pages 240-249

  Tsai, Yau Sheng ^a   Kim, Hyo Jeong ^b   Takahashi, Nobuyuki ^a   Kim, Hyung Suk ^a   Hagaman, John R ^a   Kim, Jason K ^b   Maeda, Nobuyo ^a,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAT; GLUCOSE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ABDOMINAL FAT; ADIPOCYTE; ADIPOSE TISSUE; ANGIOTENSINOGEN GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BROWN ADIPOSE TISSUE; CELL DIFFERENTIATION; CONTROLLED STUDY; FAT DISTRIBUTION; GENE; GENE EXPRESSION; GENE MUTATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HOMOZYGOSITY; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIGAND BINDING; LIGAND BINDING DOMAIN; LIPID DIET; LIPID METABOLISM; MOUSE; MOUSE STRAIN; NONHUMAN; OBESITY; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN DOMAIN; SUBCUTANEOUS FAT;

ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; DIETARY FATS; ENERGY METABOLISM; FEMALE; HUMANS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; MALE; MICE; MUTATION, MISSENSE; PHENOTYPE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 4043151601     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200420964     Document Type: Article

References (50)

1. Reaven, G.M. 1988. Role of insulin resistance in human disease. Diabetes. 37:1595-1607.
2. Berger, J., and Mollet, D.E. 2002. The mechanisms of action of PPARs. Annu. Rev. Med. 53:409-435.
3. Tontonoz, P., Hu, E., and Spiegelman, B.M. 1994. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 79:1147-1156.
4. Barak, Y., et al. 1999. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell. 4:585-595.
5. Kubota, N., et al. 1999. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell. 4:597-609.
6. Savage, D.B., et al. 2003. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome prolifetator-activated receptor-gamma. Diabetes. 52:910-917.
7. Agarwal, A.K., and Garg, A. 2002. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J. Clin. Endocrinol. Metab. 87:408-411.
8. Hegele, R.A., Cao, H., Ftankowski, C., Mathews, S.T., and Leff, T. 2002. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes. 51:3586-3590.
9. Deeb, S.S., et al. 1998. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20:284-287.
10. Ristow, M., Muller-Wieland, D., Pfeiffer, A., Krone, W., and Kahn, C.R. 1998. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N. Engl J. Med. 339:953-959.
11. Barroso, I., et al. 1999. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 402:880-883.
12. Stamler, R., Stamler, J., Riedlinger, W.F., Algera, G., and Roberts, R.H. 1978. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA. 240:1607-1610.
13. Bonora, E., et al. 1998. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 47:1643-1649.
14. Ginsberg, H.N. 2000. Insulin resistance and cardiovascular disease. J. Clin. Invest. 106:453-458.
15. Engeli, S., Negrel, R., and Sharma, A.M. 2000. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension. 35:1270-1277.
16. Hainault, I., et al. 2002. Adipose tissue-specific increase in angiotensinogen expression and secretion in the obese (fa/fa) Zucker rat. Am. J. Physiol. Endocrinol. Metab. 282:E59-E66.
17. Massiera, F., et al. 2001. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J. 15:2727-2729.
18. Dubey, R.K., Zhang, H.Y., Reddy, S.R., Boegehold, M.A., and Kotchen, T.A. 1993. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am. J. Physiol. 265:R726-R732.
19. Ogihara, T., Rakugi, H., Ikegami, H., Mikami, H., and Masuo, K. 1995. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am. J. Hypertens. 8:316-320.
20. Marx, N., Schonbeck, U., Lazar, M.A., Libby, P., and Plutzky, J. 1998. Peroxisome prolifetator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. 83:1097-1103.
21. Delerive, P., et al. 1999. Petoxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ. Res. 85:394-402.
22. Marx, N., Bourcier, T., Sukhova, G.K., Libby, P., and Plutzky, J. 1999. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb. Vasc. Biol. 19:546-551.
23. Yang, T., et al. 1999. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am. J. Physiol. 277:F966-F973.
24. Takeda, K., et al. 2000. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation. 102:1834-1839.
25. Matsubara, H. 1998. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ. Res. 83:1182-1191.
26. Miles, P.D., Barak, Y., He, W., Evans, R.M., and Olefsky, J.M. 2000. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J. Clin. Invest. 105:287-292.
27. Asakawa, M., et al. 2002. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation. 105:1240-1246.
28. Kulkarni, R.N., et al. 2003. Impact of genetic background on development of hyperinsulinemia and diabetes in insulin receptor/insulin receptor substrate-1 double heterozygous mice. Diabetes. 52:1528-1534.
29. Kido, Y., Philippe, N., Schaffer, A.A., and Accili, D. 2000. Genetic modifiers of the insulin resistance phenotype in mice. Diabetes. 49:589-596.
30. Savage, D.B., et al. 2002. Digenic inheritance of severe insulin resistance in a human pedigree. Nat. Genet. 31:379-384.
31. Zhang, C.Y., et al. 2001. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell. 105:745-755.
32. Tuttle, R.L., et al. 2001. Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat. Med. 7:1133-1137.
33. Medvedev, A.N., Snedden, S.K., Raimbault, S., Ricquier, D., and Collins, S. 2001. Transcriptional regulation of the mouse uncoupling protein-2 gene. Double E-box motif is required for peroxisome proliferator-activated receptor-gamma-dependent activation. J. Biol. Chem. 276:10817-10823.
34. Montague, C.T., and O'Rahilly, S. 2000. The perils of portliness: causes and consequences of visceral adiposity. Diabetes. 49:883-888.
35. Kelly, I.E., Han, T.S., Walsh, K., and Lean, M.E. 1999. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care. 22:288-293.
36. Arioglu, E., et al. 2000. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann. Intern. Med. 133:263-274.
37. Laplante, M., et al. 2003. PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion. Diabetes. 52:291-299.
38. Montague, C.T., et al. 1998. Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes. 47:1384-1391.
39. Atzmon, G., et al. 2002. Differential gene expression between visceral and subcutaneous fat depots. Horm. Metab. Res. 34:622-628.
40. Ferrari, P., and Weidmann, P. 1990. Insulin, insulin sensitivity and hypertension. J. Hypertens. 8:491-500.
41. Walker, A.B., Chattington, P.D., Buckingham, R.E., and Williams, G. 1999. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes. 48:1448-1453.
42. Bunting, M., Bernstein, K.E., Greet, J.M., Capecchi, M.R., and Thomas, K.R. 1999. Targeting genes for self-excision in the germ line. Genes Dev. 13:1524-1528.
43. Piedrahita, J.A., Zhang, S.H., Hagaman, J.R., Oliver, P.M., and Maeda, N. 1992. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 89:4471-4475.
44. Glorian, M., et al. 2001. A single element in the phosphoenolpyruvate carboxykinase gene mediates thiazolidinedione action specifically in adipocytes. Biochimie. 83:933-943.
45. Pende, M., et al. 2000. Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature. 408:994-997.
46. Yamauchi, T., et al. 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7:941-946.
47. Kim, J.K., et al. 2000. Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. J. Clin. Invest. 105:1791-1797.
48. Krege, J.H., Hodgin, J.B., Hagaman, J.R., and Smithies, O. 1995. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension. 25:1111-1115.
49. Butz, G.M., and Davisson, R.L. 2001. Long-term telemetric measurement of cardiovascular parameters in awake mice: a physiological genomics tool. Physiol. Genomics. 5:89-97.
50. Oliverio, M.I., Best, C.F., Smithies, O., and Coffman, T.M. 2000. Regulation of sodium balance and blood pressure by the AT(1A) receptor for angiotensin II. Hypertension. 35:550-554.